PMID- 21435434
OWN - NLM
STAT- MEDLINE
DCOM- 20110715
LR  - 20211020
IS  - 1525-2191 (Electronic)
IS  - 0002-9440 (Print)
IS  - 0002-9440 (Linking)
VI  - 178
IP  - 4
DP  - 2011 Apr
TI  - Assessment of Topoisomerase II alpha status in breast cancer by quantitative PCR, 
      gene expression microarrays, immunohistochemistry, and fluorescence in situ 
      hybridization.
PG  - 1453-60
LID - 10.1016/j.ajpath.2010.12.042 [doi]
AB  - Anthracyclines are frequently used for the treatment of breast cancer and 
      topoisomerase II alpha (TOP2A) is considered to be the molecular target. Numerous 
      studies have evaluated the predictive value of TOP2A using different 
      methodological approaches and inconsistent results have been reported. Indeed, 
      the correlation between techniques for the assessment of TOP2A status has not 
      been well evaluated. In this study, we determined TOP2A status in 61 breast tumor 
      samples by real-time PCR, DNA microarrays, immunohistochemistry (IHC), and 
      fluorescence in situ hybridization (FISH), and then evaluated these results with 
      clinical-pathological features and breast cancer intrinsic subtypes. First, we 
      observed a statistical significant correlation of TOP2A gene expression between 
      real-time PCR and microarrays (Pearson coefficient, 0.816; P < 0.001), and both 
      predicted TOP2A IHC results fairly well (area under the curve > 0.74). In 
      contrast, poor agreement between FISH and IHC data was observed (k: 0.134). 
      Secondly, TOP2A expression was found significantly associated with cell 
      proliferation, and with the highly proliferative Luminal B, Her2-enriched and 
      Basal-like intrinsic subtypes. In conclusion, TOP2A expression in breast cancer 
      was associated with high proliferation and aggressive tumor subtypes and appears 
      to be independent of its amplification status. All of these features should be 
      taken into consideration when assessing the predictive value of TOP2A for 
      anthracycline-based chemotherapy.
CI  - Copyright (c) 2011 American Society for Investigative Pathology. Published by 
      Elsevier Inc. All rights reserved.
FAU - Romero, Atocha
AU  - Romero A
AD  - Department of Medical Oncology, Hospital Clinico San Carlos, Madrid, Spain.
FAU - Martin, Miguel
AU  - Martin M
FAU - Cheang, Maggie C U
AU  - Cheang MC
FAU - Lopez Garcia-Asenjo, Jose Antonio
AU  - Lopez Garcia-Asenjo JA
FAU - Oliva, Belen
AU  - Oliva B
FAU - He, Xiaping
AU  - He X
FAU - de la Hoya, Miguel
AU  - de la Hoya M
FAU - Garcia Saenz, Jose Angel
AU  - Garcia Saenz JA
FAU - Arroyo Fernandez, Manuel
AU  - Arroyo Fernandez M
FAU - Diaz Rubio, Eduardo
AU  - Diaz Rubio E
FAU - Perou, Charles M
AU  - Perou CM
FAU - Caldes Llopis, Trinidad
AU  - Caldes Llopis T
LA  - eng
GR  - P30 ES010126/ES/NIEHS NIH HHS/United States
GR  - P50 CA058223/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Pathol
JT  - The American journal of pathology
JID - 0370502
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Poly-ADP-Ribose Binding Proteins)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 5.99.1.3 (DNA Topoisomerases, Type II)
RN  - EC 5.99.1.3 (TOP2A protein, human)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antigens, Neoplasm/*biosynthesis/*genetics
MH  - Biopsy
MH  - Breast Neoplasms/*enzymology
MH  - Cell Proliferation
MH  - DNA Topoisomerases, Type II/*biosynthesis/*genetics
MH  - DNA-Binding Proteins/*biosynthesis/*genetics
MH  - Female
MH  - *Gene Expression Regulation, Enzymologic
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Immunohistochemistry/methods
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Middle Aged
MH  - Oligonucleotide Array Sequence Analysis
MH  - Poly-ADP-Ribose Binding Proteins
MH  - Polymerase Chain Reaction/methods
MH  - Receptor, ErbB-2/metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
PMC - PMC3078442
EDAT- 2011/03/26 06:00
MHDA- 2011/07/16 06:00
PMCR- 2012/04/01
CRDT- 2011/03/26 06:00
PHST- 2010/08/09 00:00 [received]
PHST- 2010/12/03 00:00 [revised]
PHST- 2010/12/23 00:00 [accepted]
PHST- 2011/03/26 06:00 [entrez]
PHST- 2011/03/26 06:00 [pubmed]
PHST- 2011/07/16 06:00 [medline]
PHST- 2012/04/01 00:00 [pmc-release]
AID - S0002-9440(11)00042-3 [pii]
AID - AJPA217 [pii]
AID - 10.1016/j.ajpath.2010.12.042 [doi]
PST - ppublish
SO  - Am J Pathol. 2011 Apr;178(4):1453-60. doi: 10.1016/j.ajpath.2010.12.042.